FP7 HEALTH - hovedområdene i det tematiske programmet

(1)

Health FP7

UMB 27. mai 2011 Seniorrådgiver Berit Nygaard

(2)

FP7 HEALTH - hovedområdene i det tematiske programmet

Pilla 1 ll Pill 3

Pillar 1

Bioteknologi, generiske

Pillar 2

Translasjons- forskning – de

Pillar 3

Forebyggende

helse og

_Innovative^The

generiske

metoder og medisinske teknologier

forskning de store folke- sykdommene

helse og helsetjeneste-

forskning

Innovative Medicines

Initiative

teknologier

Pillar 4 Implementering av FP7&EU politikk: fremtidige behov, formidling

P t d l d f k i dt f k i

Programmet adresserer grunnleggende forskning, anvendt forskning, translasjonsforskning samt kliniske studier

(3)

H l h 6 l i

Health – 6. utlysning Prioriteringer

Prioriteringer

 Aktiv og sunn aldring Aktiv og sunn aldring

 SMB-relevant forskning (

15-50% i mange prosjekter)

 Medisinske teknologier

 Sjeldne sykdommer Sjeldne sykdommer

 Forskerdrevne kliniske studier

 Formidling og resultatspredning

(4)

H l h 6 l i

Health – 6. utlysning Strategiske valg

Strategiske valg

 Konsentrasjon av midlene – mange underområder lukket

 37 temaer/problemstillinger («topics») 37 temaer/problemstillinger ( topics )



Ca halvparten krav om/fordel med SMB-inklusjon

B d j tt å 620 ill E

 Budsjett på ca 620 mill Euro

 To-trinns behandling av alle søknader

(5)

H l h 6 l i

Health – 6. utlysning

Annen viktig informasjon Annen viktig informasjon

 Internasjonalt samarbeid (med tredje land)

 Sammen med programmene KBBE, ICT og SHH bidrar HEALTH med forskning for å realisere

bidrar HEALTH med forskning for å realisere

European Innovation Partnership (EIP) «healthy aging»

 Viktig å adressere potensielle etiske utfordringer i prosjektet p j

 Redusere bruk av forsøksdyr i forskningen

 Tilstrebe kjønnsbalanse i forskergruppene

(6)

Utlysningsteksten (obs utkast) (Orientation Paper 2012) offentliggjort medio mai

CORDIS:

http://cordis.europa.eu/fp7/health/home_en.html Publisering av utlysningen planlagt til 20. juli 2011 Tentative søknadsfrister (stage 1)

 27. september (3 prosjekter) og 4. oktober (resten

(7)

H l h 6 l i

Health – 6. utlysning

Underområder som er lukket

 High-throughput research Pilar 1

 Suitability, safety, efficacy of therapiesy, y, y p

 Brain and brain-related diseases Pilar 2

 Anti-microbial drug resistanceg

 Potentially new and re-emerging epidemics

 Neglected infectious diseasesg

 Cancer

 Cardiovascular diseases

 Translating the results of clinical research Pilar 3 outcome into clinical practice

 Health promotion and prevention

(8)

H l h 6 l i

Health – 6. utlysning

 Antall partnere (utover min. 3)

i konsortiet bestemmes

av søker

 Sammensetning av konsortiet*

 Prosjektets varighet*

av søker – fleksibelt Prosjektets varighet

* Det kan være andre anbefalinger for Det kan være andre anbefalinger for enkelte tema

(9)

1 Bi h l i l d di l

D t ti di i d it i

1. Biotechnology, generic tools and medical technologies for human health (155 mill. €) Detection, diagnosis and monitoring

 Development of technologies with a view to patient group stratification for personalised patient group stratification for personalised medicine applications

Innovative therapeutic approaches and i t ti

interventions

 Innovative approaches to solid organ transplantation

transplantation

 Medical technology for transplantation and bioartificial organs

I ti t t i f t l ti f t ll

 Innovative strategies for translation of stem cell based therapies in regenerative medicine

 Targeted nucleic acid delivery as innovative therapeutic or prophylactic approach

(10)

2 T l i h f h h l h

Integrating biological data and processes:

2. Translating research for human health (375 mill. €)

g g g p

Large-scale data gathering

 Support for international rare disease researchSupport for international rare disease research

 Clinical utility of –omics for better diagnosis of rare diseases

D t b bi b k d “ li i l bi

 Databases, biobanks and “clinical bio- informatics” hub for rare diseases

 Validation of -omics based biomarkers for diseases affecting the elderly

 Statistical methods for collection and analysis of -omics data

(11)

2 T l ti h f h h lth (375 ill €) 2. Translating research for human health (375 mill. €)

Systems biology/medicine

 Systems medicine: SME-driven research Systems medicine: SME driven research applying systems biology approaches to adress medical and clinical needs

 Applying systems biology approaches

 Applying systems biology approaches for understanding complex human diseases and their co-morbidity

 Preparing for the future research and

 Preparing for the future research and innovation activities in systems

medicine

(12)

2 T l i h f h h l h

2. Translating research for human health

(375 mill. €)

Research on the brain and related diseases,

human development and ageing Human development and ageing

 Integrative systems biology and comparative genomics for studying human ageing and/or most common age-related diseases

 Investigator-driven clinical trials for optimisation of management of elderly patients with multiple diseases

(13)

2 T l i h f h h l h

2. Translating research for human health

(375 mill. €)

Translational research in major infectious

diseases: to confront threats to public health Cross cutting

 Diagnostics for infectious diseases

 ERA-NET on infectious diseases

HIV/AIDS, malaria and tuberculosis

 Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis

a d/o epat t s

 Co-morbidity between infectious and non- communicable diseases

P ti d t t t f HIV/AIDS l i

 Preventioen and treatment for HIV/AIDS, malaria, tuberculosis

 Low-cost interventions for disease control in

tti

resource poor settings

(14)

2 T l i h f h h l h

2. Translating research for human health

(375 mill. €)

Translational research in other major diseases

Diabetes and obesity

 Innovative approach to manage diabetespp g

 Investigator-driven clinical trials for type 1 diabetes research

Rare diseases

 Preclinical and/or clinical development of substances with a clear potential as orphan drugsp p g

 Observational trials in rare diseases

 Bets practice and knowledge sharing in the clinical management of rare diseases

management of rare diseases

(15)

2 T l i h f h h l h

2. Translating research for human health

(375 mill. €)

Translational research in other major j

diseases

Other chronic diseases

 Technological approaches to combating sensory impairments

 Biomarkers and diagnostics for chronic g inflammatory diseases of the joints and/or digestive system

(16)

3 O i i i h d li f h l h E 3. Optimising the delivery of healthcare to European

citizens (50 mill. €)

Quality, efficiency and solidarity of health- care systems including transnational health systems

 Improving the organisation of health service delivery

h d l i f h l h h l

 New methodologies for health technology assessment

 Social innovation for ageing researchSocial innovation for ageing research

International public health and health systems

 Research on health systems and services in low- and middle-income countries

(17)

4 A i h H l h h

4. Actions across the Health theme

(20 mill. €)

Coordination and Support Actions pp

 Network to encourage knowledge transfer activity in FP-funded health research

Training actions linked to intellectual property

 Training actions linked to intellectual property rights management and knowledge transfer

 Support for Presidency events: Organisation of supporting actions and events related to the supporting actions and events related to the Presidency of the European Union

 Communicating the benefits of European research to the general public

to the general public

 Prepare the future for health research and innovation

(18)

FP7 H lth 2007 2013

FP7 Health 2007–2013

Resultater per 31.12.2010

Sammenlikning nordiske land

Ant søknader Ant prosjekter Suksessrate (%)

Sammenlikning nordiske land

Ant. søknader Ant. prosjekter Suksessrate (%)

DK 444 111 25

FI 366 91 26

NO

224 59

26 SE 754 197 26

(19)

2012 tl i i d t ti k

2012-utlysninger i andre tematiske programmer med relevans for helse



KBBE – Food, Agriculture, Fisheries and Biotechnology

 Food, health, diet-related diseases, consumer behaviourFood, health, diet related diseases, consumer behaviour



ICT - Information and Communications Technologies

 Virtual Physiological Humany g



NMP – Nanosciences, Nanotechnologies, Materials and new Production Technologies

(NMP)

 Nanotech. systems for diagnosis & treatment, nanomedicine, toxicity of nanoparticles



SHH – Socioeconomic Sciences and Humanities



SHH – Socioeconomic Sciences and Humanities

 Making longevity an asset for economic and social development, European childhood and youth survey

(20)

FP7 H lth 2007 2013 FP7 Health 2007–2013

7. utlysning (siste) – juli 2012 tentativt:



Hjernen og hjernesykdommer

7. utlysning (siste) juli 2012 tentativt:

 Trolig «Year of the Brain»



Kreft



Hjerte-karsykdommer



Vaksiner og medisiner - parasittsykdommer g p y



Comparative Effectivness Studies



Helseundersøkelser – helsefremme/forebygging Helseundersøkelser helsefremme/forebygging



Stor andel prosjekter med SMB-deltakelse

(21)

FP7 H l h H d fi ? FP7 Health - Hvordan finne partnere?

 www.fitforhealth.eu – database for partnersøk

P t i ll j kt t å d 10 j i i

 Potensielle prosjektpartnere – åpen dag 10. juni i Brüssel

http://ec europa eu/research/health/events en html http://ec.europa.eu/research/health/events_en.html

 Prosjektdatabase:

www.healthcompetence.eu

 Åpen informasjonsdag i Brüssel 9. juni p j g j

http://ec.europa.eu/research/health/events-05en.html

(22)

l i il

Utlysning – pilot JPI

Neurodegenerative Disease (Al h i )

(Alzheimer)

 http://www.neurodegenerationresearch.eu/home/

 Transnational call for optimisation of

biomarkers and harmonisation of their use

 Søknadsfrist 5. september 2011

Kontaktperson NFR: Karianne Solaas; [email protected]

NevroNor-koordinator

(23)

FP7 H lth 2007 2013

Kontaktpersoner

FP7 Health 2007–2013

Kontaktpersoner



NCP Health: Berit Nygaard, 22037174, [email protected]

Øk i fi

Y F

22037375

f@



Økonomi og finans: Yngve Foss, 22037375, [email protected]



IMI: Hans M. Borchgrevink, 22037160, [email protected]



Research infrastructure: Solveig Flock, 22037034, [email protected]



ERC: Per Ivar Høvring, 22037426 [email protected]



SMB: Vebjørn Walderhaug, 22037304, [email protected]

(24)

Takk for oppmerksomheten! f pp

(25)

M li h t i d t ti k

Muligheter i andre tematiske program

KBBE: complementary to Theme Health

– KBBE.2012.2.1-01: Role of health-related symbols and KBBE.2012.2.1 01: Role of health related symbols and claims in consumer behaviour

– KBBE 2012 2 2-01: Beneficial effects of bioactive KBBE.2012.2.2 01: Beneficial effects of bioactive compounds in humans

KBBE 2012 2 2 02: Study on the needs for food and – KBBE.2012.2.2-02: Study on the needs for food and

health research infrastructures

KBBE 2012 2 2 03 I t f lif t l ll b i d – KBBE.2012.2.2-03: Impact of lifestyle on well-being and

diet-related disease

K KBBE.2012.2.1-01: Role of health-related

symbols and claims in consumer behaviour

(26)

Muligheter i andre tematiske program Muligheter i andre tematiske program

Social Sciences and Humanities SSH: complementary to Theme Health SSH: complementary to Theme Health

– ERA-net Coordinating research economic agendas – Making longevity an asset for economic and social

development

– A European childhood and youth survey

– Forward looking tools and methods for answering Forward looking tools and methods for answering

major societal challenges

(27)

NMP: complementary to Theme Health NMP: complementary to Theme Health

– NMP.2012.1.2-2: Development and phase-I clinical trials of novel therapeutic nanotechnology-enabled systems for of novel therapeutic nanotechnology-enabled systems for the diagnosis and treatment of atherosclerosis

NMP 2012 1 2 3: ERA NET on nanomedicine – NMP.2012.1.2-3: ERA-NET on nanomedicine

– NMP.2012.1.3-1: Systematic investigations of the mechanisms and effects of engineered nanomaterial mechanisms and effects of engineered nanomaterial interactions with living systems and/or the environment NMP 2012 1 3 2 : Modelling toxicity behaviour of

– NMP.2012.1.3-2 : Modelling toxicity behaviour of engineered nanoparticles

NMP 2012 2 2 1 Bi t i l f i d f

– NMP.2012.2.2-1: Biomaterials for improved performance

of medical implants

(28)